Reporting of adverse events in randomized controlled trials of highly active antiretroviral therapy: systematic review
The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
OBJECTIVES: Our objectives were to systematically assess the quality of reporting of adverse events (AEs) in publications of randomized trials of highly active antiretroviral therapy (HAART), and to examine whether reporting quality affects the effect estimates reported for AEs. METHODS: We searched the PubMed, Cochrane library and EMBASE electronic databases up to December 2008. We included all published randomized controlled trials assessing HAART for treatment-naive adult HIV-infected individuals, with 48 weeks' follow-up. The quality of AE reporting was extracted according to CONSORT guidelines. We pooled the relative risks for AEs and compared results by sponsorship and different reporting methods. RESULTS: Forty-nine trials, including 19 882 patients, published between 2000 and 2008, met the inclusion criteria. Only one of the trials reported on AE collection methods. Twenty-six trials reported only AEs attributed to drugs, 17 of which did not refer to the attribution methods. AE reporting was nearly always selective and selection criteria were highly variable, based on severity grading or occurrence threshold. Presentation of AEs above an occurrence threshold was more common in studies sponsored by industry (30/31) than in studies sponsored by non-profit organizations (3/18). Moreover, we showed that differences in the methods of reporting AEs may affect the results reported for AEs. No significant improvement in AE reporting was seen over this period. CONCLUSIONS: We found substantial variability in AE reporting. Variability was influenced by sponsor identity and affected outcomes. These facts obstruct our ability to choose HAART based on currently published data.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Moher, D. (2001) · JAMA · doi:10.1001/jama.285.15.1987 · Cited by 2,545
Scope and Impact of Financial Conflicts of Interest in Biomedical Research: A Systematic Review
Bekelman, J. E., Li, Y., & Gross, C. P. (2003) · JAMA · doi:10.1001/jama.289.4.454 · Cited by 1,816 · cited 1×
“Industry sponsorship has been associated previously with pro-industry study design, with regard to the selection of the control group or drug dosing and pro-industry conclusions.(17) We show that AE reporting might also be affected, although some diversity might be expected due to the inherent differences between indu…”
Better Reporting of Harms in Randomized Trials: An Extension of the CONSORT Statement
Ioannidis, J. P. A., Evans, S. J. W., Gøtzsche, P. C., O'Neill, R. T., Altman, D. G., Schulz, K., Moher, D., & for the CONSORT Group* (2004) · Annals of Internal Medicine · doi:10.7326/0003-4819-141-10-200411160-00009 · Cited by 1,593
Gallant, J. E. (2004) · JAMA · doi:10.1001/jama.292.2.191 · Cited by 1,341
Bent, S., Padula, A., & Avins, A. L. (2006) · Annals of Internal Medicine · doi:10.7326/0003-4819-144-4-200602210-00007 · Cited by 177
Completeness of Safety Reporting in Randomized Trials: An Evaluation of 7 Medical Areas
Ioannidis, J. P. A., & Lau, J. (2001) · JAMA · doi:10.1001/jama.285.4.437 · Cited by 3
Cited by
Industry sponsorship and research outcome
Lundh, A., Lexchin, J., Mintzes, B., Schroll, J. B., & Bero, L. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.mr000033.pub3 · Cited by 1,697
Reducing waste from incomplete or unusable reports of biomedical research
Glasziou, P., Altman, D. G., Bossuyt, P., Boutron, I., Clarke, M., Julious, S., Michie, S., Moher, D., & Wager, E. (2014) · The Lancet · doi:10.1016/s0140-6736(13)62228-x · Cited by 1,319
A catalogue of reporting guidelines for health research
Simera, I., Moher, D., Hoey, J., Schulz, K. F., & Altman, D. G. (2010) · European Journal of Clinical Investigation · doi:10.1111/j.1365-2362.2009.02234.x · Cited by 1,047
Turner, L., Shamseer, L., Altman, D. G., Weeks, L., Peters, J., Kober, T., Dias, S., Schulz, K. F., Plint, A. C., & Moher, D. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.mr000030.pub2 · Cited by 740
Industry sponsorship and research outcome
Lundh, A., Sismondo, S., Lexchin, J., Busuioc, O. A., & Bero, L. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.mr000033.pub2 · Cited by 605
Simera, I., Moher, D., Hirst, A., Hoey, J., Schulz, K. F., & Altman, D. G. (2010) · BMC Medicine · doi:10.1186/1741-7015-8-24 · Cited by 590
Jin, Y., Sanger, N., Shams, I., Luo, C., Shahid, H., Li, G., Bhatt, M., Zielinski, L., Bantoto, B., Wang, M., et al. (2018) · Journal of Multidisciplinary Healthcare · doi:10.2147/jmdh.s155103 · Cited by 134
Smith, S. M., Wang, A. T., Katz, N. P., McDermott, M. P., Burke, L. B., Coplan, P., Gilron, I., Hertz, S. H., Lin, A. H., Rappaport, B. A., et al. (2013) · Pain · doi:10.1016/j.pain.2013.03.003 · Cited by 58
Mbuagbaw, L., Kosa, S. D., Lawson, D. O., Stalteri, R., Olaiya, O. R., Alotaibi, A., & Thabane, L. (2019) · Pilot and Feasibility Studies · doi:10.1186/s40814-019-0500-z · Cited by 57
Cornelius, V. R., Sauzet, O., Williams, J. E., Ayis, S., Farquhar-Smith, P., Ross, J. R., Branford, R. A., & Peacock, J. L. (2013) · Pain · doi:10.1016/j.pain.2012.08.012 · Cited by 49
“Although the routine collection and reporting to regulatory authorities should have improved as a result of regulation, the reporting of these processes in publications still seems to be substandard [4,18,21].”
BackgroundBashir, R., Bourgeois, F. T., & Dunn, A. G. (2017) · Systematic Reviews · doi:10.1186/s13643-017-0518-3 · Cited by 47
Favier, R., & Crépin, S. (2018) · Clinical Trials · doi:10.1177/1740774518760565 · Cited by 19
“In contrast, other studies found improvements in the global score, specific recommendations or space in results sections allocated during successive years or when comparing score before and after the publication of the CONSORT Harms extension in 2004.(13,16,56,59,62,63) Haidich et al.”
Result
Metadata
- Authors
- Chowers, M. Y., Gottesman, B. S., Leibovici, L., Pielmeier, U., Andreassen, S., & Paul, M.
- Venue
- Journal of Antimicrobial Chemotherapy
- Publisher
- Oxford University Press (OUP)
- Published
- 2009-05-28
- Volume
- 64
- Issue
- 2
- Pages
- 239-250
- ISSN
- 0305-7453 (ISSN-L)
- 1460-2091
- OpenAlex
- W2119755091
- Cited by
- 53
- References
- 7
- FWCI
- 0.40
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.